Melioidosis in Italy

24 views
Skip to first unread message

Gavin Koh

unread,
Oct 21, 2022, 8:21:59 AM10/21/22
to melio...@googlegroups.com, Alberto Gaviraghi
Dear friends,

I've been asked to comment on this article from Italy claiming to find B. pseudomallei in drinking water in Bologna. The identification method was API 20 NE but I am not clear that that is appropriate for an environmental sample.

Has anyone reviewed this article before and what are your thoughts?

Gavin
b. pseudomallei a bologna.pdf

Direk Limmathurotsakul

unread,
Oct 22, 2022, 12:11:19 AM10/22/22
to melio...@googlegroups.com, Alberto Gaviraghi

Dear Gavin,

 

I did check that one when we did the ‘burden of melioidosis’ modelling paper (picture below).

It was excluded from the analysis. We note in the methods that we exclude unclear evidence.

It did not show in the main Figure in the paper. (There is no black dot in Italy)

(There is no black dot in France as well; as that one single study of environmental in ‘Jardin des Plantes’ was considered unclear).

 

On www.melioidlsis.info website ; map page. If users click ‘occurrence of melioidosis’ ; users can see our footnotes for details (picture below)

(we haven’t updated the map on the website for a while; so the US point hasn’t pop up yet and things in Australia need checking and updating as well)

(Nonetheless, I haven’t come across any new info that will change the situation for Italy [as Star and Footnote No 2] on the map).

 

We hope to have time to update the map on the website soon.

 

Kind regards,

Direk

 

 

--
You received this message because you are subscribed to the Google Groups "Melioidosis.info" group.
To unsubscribe from this group and stop receiving emails from it, send an email to melioidosis...@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/melioidosis/CAKsZGzYC5GHCjG8oVF%3DioG7EBmAZq170VBTiGAgXJL5%3DB-W9pA%40mail.gmail.com.

Bart Currie

unread,
Oct 22, 2022, 1:32:16 AM10/22/22
to melio...@googlegroups.com, Alberto Gaviraghi
Further to Direk’s summary, I agree those environmental bacteria from Italy may well represent incorrect ID - and unless the authors have some frozen isolates for confirmatory testing by PCR (eg TTSI, others) and WGS (from which MLST ST can be derived in silico), we will never know for sure. As B. pseudomallei is being increasingly found in new geographical locations, having WGS clarifies the relationships with the global dataset of Bp WGS and helps resolve epidemiological questions of if is it truly endemic or has it been introduced/imported. And the USA CDC has now confirmed both scenarios in the continental USA in the last 2 years. So much more to uncover and learn.
Bart

From: melio...@googlegroups.com <melio...@googlegroups.com> on behalf of Direk Limmathurotsakul <di...@tropmedres.ac>
Sent: Saturday, October 22, 2022 1:40:59 PM
To: melio...@googlegroups.com <melio...@googlegroups.com>
Cc: Alberto Gaviraghi <582...@lstmed.ac.uk>
Subject: RE: [Melioidosis] Melioidosis in Italy
 

xiaqi...@sina.com

unread,
Oct 22, 2022, 3:52:49 AM10/22/22
to melioidosis
  • I totally agree with Professor Bart Currie.



--------------------------------
Qianfeng Xia Ph.D.
Professor, Dean of School of Tropical Medicine
Hainan Medical University,
No. 3, Xueyuan Road, Longhua District,
Haikou, 571199, China


----- 原始邮件 -----
发件人:Bart Currie <Bart....@menzies.edu.au>
收件人:"melio...@googlegroups.com" <melio...@googlegroups.com>
抄送人:Alberto Gaviraghi <582...@lstmed.ac.uk>
主题:Re: [Melioidosis] Melioidosis in Italy
日期:2022年10月22日 13点32分
image001.png
image002.png

David Dance

unread,
Oct 22, 2022, 4:33:18 AM10/22/22
to melio...@googlegroups.com

Dear Gavin et al.

 

I do remember this paper being published and I was very sceptical about it at the time, and still am.  I think, as Bart and Direk have implied, that it is insufficient to rely purely on API 20NE for identification, particularly from non-clinical samples in a non-endemic area.  I believe I wrote to the authors at the time in the hope that they might be able to make their isolates available for further study but never received a response, although I cannot locate the correspondence after all this time!  Direk and I discussed whether or not to include this in his modelling analysis, as he describes below, and we decided to exclude it.

 

BW

 

David

David Dance

unread,
Oct 22, 2022, 4:34:01 AM10/22/22
to melio...@googlegroups.com

Dear Gavin et al.

 

I do remember this paper being published and I was very sceptical about it at the time, and still am.  I think, as Bart and Direk have implied, that it is insufficient to rely purely on API 20NE for identification, particularly from non-clinical samples in a non-endemic area.  I believe I wrote to the authors at the time in the hope that they might be able to make their isolates available for further study but never received a response, although I cannot locate the correspondence after all this time!  Direk and I discussed whether or not to include this in his modelling analysis, as he describes below, and we decided to exclude it.

 

BW

 

David

 


Reply to: "melio...@googlegroups.com" <melio...@googlegroups.com>
Date: Saturday, 22 October 2022 at 08:53
To: melioidosis <melio...@googlegroups.com>

Subject: 回复:Re: [Melioidosis] Melioidosis in Italy

Mark Mayo

unread,
Oct 23, 2022, 7:15:46 PM10/23/22
to melio...@googlegroups.com

Hello Gavin, I also agree with Bart and David comments about the API 20 NE results.

In this paper https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2168515/ the accuracy was good, but Bp can have many different API 20 NE profiles, I found I had many different profiles as well from some of my earlier testing of Bp using API 20 NE.

Also the interpretation of some of the test results on the panel can lead to incorrect results or species identification. Some near neighbour species such as B.thailandensis can also be identified as Bp.

Unless as suggested they have the isolates for further testing to confirm the Bp identification, I would find it hard to call the isolates Bp based only on API 20 NE results.  

 

Regards Mark

 

Mark Mayo,

Melioidosis Program Manager/Senior Researcher

Associate Deputy Director of Indigenous Leadership and Engagement

T: (08) 89 468 564 | F: (08) 89 468 464 | M: 0439 825 787 | mark...@menzies.edu.au | www.menzies.edu.au Twitter-Iconfacebook_logo 

 

 

PO Box 41096, Casuarina NT 0811, Australia

John Mathews Building (Bldg 58) |

Royal Darwin Hospital Campus, Rocklands Drive, Casuarina NT 0810

 

 

In the spirit of respect, Menzies School of Health Research acknowledges the people and the Elders of the Aboriginal and Torres Strait Islander Nations who are the Traditional Owners of the land and seas of Australia.

Bijayini Behera

unread,
Oct 23, 2022, 11:53:43 PM10/23/22
to melio...@googlegroups.com
Agreed Sir.  On the other hand, I would also like to draw attention to situations whereas clinical melioidosis cases are treated inadequately because isolates are being identified as B cepacia complex by Vitek 2. Stand alone pvt sector hospitals can not have molecular facilities for identification,  hence the role of AMD LFI version 2 or tests like those are needed. In addition to creating awareness,  it is the need of sensitive and specific poct,  that will go a long way. Regards Dr Bijayini 

Enoka Corea

unread,
Oct 24, 2022, 10:46:54 PM10/24/22
to melio...@googlegroups.com
We use the latex agglutination reagent from Narisara in Thailand and find it very sensitive and specific for bench top identification.

Enoka Corea

Reply all
Reply to author
Forward
0 new messages